Military Plans Hormone Tests, Retail Traders Volunteer Immediately

The U.S. military will test troops for testosterone replacement therapy. Not because they asked. Because the Pentagon decided it's time to figure out if the therapy works or if it's just expensive urine.

TRT has been around for decades. Doctors prescribe it to men with actual medical conditions. Low testosterone. Hypogonadism. The kind of thing you confirm with blood work, not a podcast. But now the military wants data on whether shoving synthetic hormones into healthy soldiers makes them better at their jobs or just angrier at PowerPoint presentations.

The research shows benefits for patients who qualify. That's the key phrase. Who qualify. Not every guy who feels tired after lunch. Not every 35-year-old who can't bench what he did in college. Men with documented deficiencies. The military will test troops to see if TRT improves performance, which sounds reasonable until you remember this is the same institution that once bought $640 toilet seats.

Questions remain about long-term risks. Heart disease. Stroke. Prostate issues. The studies aren't conclusive because most men on TRT don't stay in studies long enough. They feel better for six months, stop showing up to appointments, and then die of something unrelated twenty years later. Science calls this a confounding variable. Retail traders call it bullish.

The real concern is use among men without a medical need. Guys who take it because they saw an ad during a UFC fight. Men who think testosterone is a personality. The military testing healthy troops won't stop civilians from walking into clinics and lying about symptoms, but it might generate data showing that jamming your endocrine system for no reason is a bad idea. That data will be ignored.

The tests will cost millions. The results will be published in a journal no one reads. And every gym bro in America will continue injecting himself twice a week because his favorite influencer said it cured his anxiety.

Meanwhile, your portfolio is down 30% because you bought calls on a company that makes nothing.

Photo by Daniel on Unsplash